This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chu, Q. D. Articles by Gibbs, J. F. Search for Related Content PubMed PubMed Citation Articles by Chu, Q. D. Articles by Gibbs, J. F. Related Collections Prognostic factors

Predictive Factors Associated With Long-Term Survival in Patients With Neuroendocrine Tumors of the Pancreas

From the Department of Surgical Oncology, Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, New York.

Correspondence: Address correspondence and reprint requests to: John F. Gibbs, MD, Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263; Fax: 716-845-2320; E-mail: john.gibbs{at}roswellpark.org

Background: Neuroendocrine tumors of the pancreas are rare tumors. We identified predictive factors that are associated with long-term survival (5 years).

Methods: Fifty patients with a diagnosis of neuroendocrine tumors of the pancreas were retrospectively evaluated. The following factors were evaluated for disease-specific mortality: age, sex, primary tumor location, functional status, type of primary tumor treatment, presence or absence of liver metastases, timing of liver metastases occurrence, and type of liver metastases treatment. Aggressive treatment of the liver metastases included surgery, chemoembolization, or intrahepatic arterial infusion chemotherapy.

Results: Twenty-three patients (47%) had tumor located in the head of the pancreas, and 29 patients (58%) had nonfunctioning tumor. Thirty-nine patients (78%) had liver metastases. The median follow-up for the entire group was 35 months (range, .76–206 months). The median survival for the entire group was 40 months, and the overall 1-, 2-, and 5-year survival rates were 84%, 69%, and 36%, respectively. Factors that had a significant favorable effect on survival included curative resection of the primary tumor, metachronous liver metastases, absence of liver metastases, and aggressive treatment of the liver metastases.

Conclusions: Definitive surgical resection of the primary tumor, absence of liver metastases, metachronous liver metastases, and aggressive treatment of the liver metastases were predictors of long-term survival in patients with neuroendocrine tumors of the pancreas.

Key Words: Neuroendocrine tumors • Pancreas • Liver metastases • Predictive factors

This article has been cited by other articles:

				T. R Halfdanarson, J. Rubin, M. B Farnell, C. S Grant, and G. M Petersen Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors Endocr. Relat. Cancer, June 1, 2008; 15(2): 409 - 427. [Abstract] [Full Text] [PDF]

				D. J. Kwekkeboom, W. W. de Herder, B. L. Kam, C. H. van Eijck, M. van Essen, P. P. Kooij, R. A. Feelders, M. O. van Aken, and E. P. Krenning Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival J. Clin. Oncol., May 1, 2008; 26(13): 2124 - 2130. [Abstract] [Full Text] [PDF]

				R. Bettini, L. Boninsegna, W. Mantovani, P. Capelli, C. Bassi, P. Pederzoli, G. F. Delle Fave, F. Panzuto, A. Scarpa, and M. Falconi Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours Ann. Onc., May 1, 2008; 19(5): 903 - 908. [Abstract] [Full Text] [PDF]

				M. C. Zatelli, M. Torta, A. Leon, M. R. Ambrosio, M. Gion, P. Tomassetti, F. De Braud, G. Delle Fave, L. Dogliotti, E. C d. Uberti, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study Endocr. Relat. Cancer, June 1, 2007; 14(2): 473 - 482. [Abstract] [Full Text] [PDF]

				K. K. Kazanjian, H. A. Reber, and O. J. Hines Resection of Pancreatic Neuroendocrine Tumors: Results of 70 Cases Arch Surg, August 1, 2006; 141(8): 765 - 770. [Abstract] [Full Text] [PDF]

				P. Tomassetti, D. Campana, L. Piscitelli, R. Casadei, D. Santini, F. Nori, A. M. Morselli-Labate, R. Pezzilli, and R. Corinaldesi Endocrine pancreatic tumors: factors correlated with survival Ann. Onc., November 1, 2005; 16(11): 1806 - 1810. [Abstract] [Full Text] [PDF]

				M. A. Kouvaraki, J. A. Ajani, P. Hoff, R. Wolff, D. B. Evans, R. Lozano, and J. C. Yao Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas J. Clin. Oncol., December 1, 2004; 22(23): 4762 - 4771. [Abstract] [Full Text] [PDF]